Introduction
Expression of CD200 is an independent prognostic factor for multiple myeloma and acute myeloid leukemia, predicting reduced overall survival of these patients (Moreaux et al., 2006; Tonks et al., 2007) . CD200 is the ligand for CD200 receptor (CD200R), which is an immune inhibitory receptor expressed on myeloid and lymphoid cells and is considered an important immunological checkpoint (Wright et al., 2001; Rijkers et al., 2008) .
Immune inhibitory receptors are well recognized for their importance in the maintenance of tolerance. These immunological checkpoints prevent over-activation or improper action of the immune cells, which may lead to undesired effects such as extreme lymphoproliferation, chronic inflammation and autoimmunity. There is emerging evidence that tumor cells use these endogenous inhibitory pathways for their benefit. As a result of this, inhibitory immune pathways have become therapeutic targets to strengthen anti-tumor responses and develop (adjuvant) therapeutic strategies in cancer treatment. Recent clinical trials with blocking antibodies against the inhibitory receptors CTLA4 and PD-1 have yielded promising results (Brahmer et al., 2010; Ralph et al., 2010) . In March of this year, the blocking CTLA4 antibody Ipilimumab was approved by FDA for use in melanoma, being the first drug ever proven to prolong survival in stage IV melanoma. However, although both CTLA4 and PD-1 directly inhibit T-cells, other checkpoints might further allow enhancing the blockade indirectly, for example, on the level of antigen-presenting cell.
An antibody that blocks CD200-CD200R interaction is currently being evaluated in clinical trials (Alexion Pharmaceuticals (Cheshire, CT, USA), NCT00648739). It is thought to reverse the suppression of CD200R-expressing effector cells by blocking CD200 expressed on tumors and is thus restricted to use in the case of CD200-expressing tumors. Indeed, various studies have shown that CD200-expressing tumor cells can suppress T-cell responses in vitro and in vivo (McWhirter et al., 2006; Kretz-Rommel et al., 2007; Petermann et al., 2007; Siva et al., 2008; Pallasch et al., 2009; Wong et al., 2010) . Although it is not clear by which mechanism CD200 expression on tumors suppresses the immune system, in vitro studies suggest that blocking CD200-CD200R enhances Th1 responses (McWhirter et al., 2006; Siva et al., 2008) . No studies have evaluated CD200-CD200R blockade using endogenous tumors in in vivo models.
We set out to study whether CD200-CD200R interaction controls tolerance to external antigens and to endogenous tumors, possibly extending therapeutic application of antibodies that block CD200-CD200R interaction to a wider range of malignancies. One of the most potent tolerogenic mechanisms of the immune system is mediated by FoxP3-expressing T-regulatory (Treg) cells. Tolerance to exogenous antigens can be conferred by transfer of Treg cells from tolerized animals into naive recipients (Unger et al., 2003b) . However, in inflammatory conditions Treg cells can change their phenotype and start to produce interleukin (IL)-17, mimicking Th17 cells (Koenen et al., 2008; Zhou et al., 2008; Baban et al., 2009; Chung et al., 2009; Murphy and Stockinger, 2010) . Th17 cells specifically express the transcription factor RORg and are mostly known for their instrumental role in the development of autoimmune diseases (Fouser et al., 2008) . The role of IL-17 and Th17 cells in the tumor microenvironment is ambiguous with reports supporting pro-and anti-tumorigenic effects of IL-17, reviewed in (Maniati et al., 2010) . Th17 cells can take part in the development of anti-tumor responses by activating and/or increasing the number of tumor-penetrating effector cells (Kryczek et al., 2009; Martin-Orozco et al., 2009; Sharma et al., 2010) . In the current paper we investigated the role of CD200R signaling in the induction of tolerance toward exogenous and endogenous tumor antigens, and the role of this interaction in the generation of Treg and Th17 cells.
Results

Cd200
À/À mice have increased resistance to chemically induced tumors To study the importance of CD200R signaling in the development of endogenous tumors we used a wellestablished and broadly used two-stage carcinogenesis model leading to formation of Ras-induced skin papillomas (Quintanilla et al., 1986; Finch et al., 1996) . In this model, tumors are initiated by application of the carcinogen 7,12-dimethylbenzanthracene on the skin. Subsequent biweekly treatment of the same area for 20 weeks with the tumor promoter 12-O-tetradeconoylphorpbol-13-acetate (TPA) results in the outgrowth on of papillomas.
We observed a striking difference in papilloma outgrowth between wild-type and Cd200 À/À mice. Although all mice developed papillomas, CD200-deficient mice developed three to four times less papillomas than control mice (Figures 1a and b) . The onset of tumors was delayed in Cd200 À/À mice ( Figure 1c ) and the number of large papillomas (diameter 41 mm) in Cd200 À/À mice was significantly decreased (Figure 1d ). In general, during the entire evaluation period the number of mice with large tumors increased in wild-type and Cd200 À/À mice; however, in the Cd200 À/À group the number of mice with large tumors decreased transiently several times, suggesting a dynamic process of tumor growth and regression ( Figure 1d ).
In agreement with previous reports, CD200 was highly expressed in the skin, particularly in hair follicles (Meyer et al., 2008) . Importantly, papilloma cells from wild-type mice lacked expression of CD200, with the exception of rare CD200-positive infiltrating stroma cells (Figure 1e ). This implies an indirect role for CD200 in the induction of tumor tolerance, indeed during the carcinogenesis protocol, several weeks before the onset of macroscopic tumors, the first indication for a possible break of immune tolerance was a transient skin condition observed in the Cd200 À/À mice. It was characterized by scaly, very dry skin and disappearance of hair to a much greater extent in Cd200 À/À mice than wild-type controls, reflecting enhanced inflammation and a possible break of immune tolerance to selfantigens in the skin in the Cd200 À/À mice upon to repeated TPA application (Figures 1f and g ).
Failure to induce immune tolerance in the absence of CD200 Increased tumor resistance coexisting with increased skin inflammation in CD200-deficient mice may be caused by decreased tolerance to tumor cells due to the lack of CD200R signaling. We used a classical delayedtype hypersensitivity model to study the development of immune tolerance in Cd200 À/À mice. Upon intranasal exposure, antigen is taken up by dendritic cells (DCs), À/À mouse, CD200 (green), CD8 (red) and CD45 (blue). The papilloma cells do not express CD200, in contrast to infiltrating stroma cells and adjacent skin. Two papilloma samples from each genotype were analyzed with similar results. The dotted line indicates the tumor/ normal skin border. Pictures were taken with Â 10 objective, scale bar represents 100 mm. (f) Representative photograph of wild-type and Cd200
À/À mice after 3 weeks of carcinogenesis treatment. CD200-deficient mice develop severe skin inflammation characterized by very dry and scaly skin. (g) Incidence of very dry and scaly skin at week 3 in wild-type and Cd200 À/À mice. The condition of the skin was scored blindly. The experiment was repeated twice with similar results (n ¼ 16, n ¼ 24). Mean and s.d. of all mice are shown. Significant differences are marked with *Po0.05 (unpaired t-test).
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TP Rygiel et al processed and presented in the draining lymph nodes (LNs) by non-plasmacytoid (p) interstitial DCs, where Treg cells are induced (Wolvers et al., 1997; Tsitoura et al., 1999; Unger et al., 2003a) . Cd200 À/À and wild-type mice received ovalbumin (OVA) intranasally and were subsequently sensitized in the tail and challenged with OVA in the ear. Wild-type animals that received OVA intranasally showed a significantly lower delayed-type hypersensitivity model response than animals that had received saline (Figure 2a ). Induction of antigen-specific tolerance after intranasal OVA administration was not observed in Cd200 À/À mice ( Figure 2a ).
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To get more insight into the mechanism behind the failure of tolerance induction in Cd200 À/À mice we investigated the induction of Treg cells. Their antigenspecific regulatory capacity can be tested by transfer of splenic CD4
þ T-cells from tolerized animals, which can confer tolerance to naive recipients (Unger et al., 2003b) . To evaluate the presence of functional Treg cells in wildtype and Cd200
À/À mice intranasally exposed to OVA, naive wild-type mice were adoptively transferred with CD4 þ T-cells derived from wild-type or Cd200 À/À OVAtolerized donors. One day after CD4 þ T-cell transfer, the animals were sensitized and challenged with OVA in the tail base and ear, respectively. CD4 þ T-cell transfer from wild-type mice did transfer tolerance to naive mice, whereas CD4
þ T-cells from Cd200 À/À donors were unable to do so ( Figure 2b ). These data show that Cd200 À/À mice Figure 2 Cd200 À/À mice fail to induce tolerance to intranasally administered antigens. (a) Wild-type and Cd200 À/À mice received OVA intranasally for 3 consecutive days, followed by subcutaneous OVA/IFA injection on day 4, and OVA injection in both ear auricles on day 9. Ear thickness increase was measured as delayed-type hypersensitivity model response 24 h later. (b) After 2 weeks the ear thickness measurement shown in Figure 1a and 1 week after resensitization, naive wild-type mice received spleen CD4 þ T-cells from wild-type and Cd200 À/À mice treated intranasally with OVA. Subsequently mice received the same treatment as in Figure 1a . Data points are the mean of both ears of individual animals (n ¼ 7). Significant differences are marked with *Po0.05, **Po0.01 or ***Po0.001 (unpaired t-test). (c, d) Nose-draining LNs sections from control mice (c) or mice that received OVA intranasally 72 h earlier (d) were stained for CD200 (blue) and gp38 (red) and pictures were taken of T-cell areas. Pictures were taken with Â 20 objective, scale bar represents 50 mm. (e, f) CD200 expression was studied by fluorescence-activated cell sorting analysis of carboxyfluorescein diacetate succinimidyl ester labeled OVA-specific OTII in (e) nose draining, cervical LNs and in (f) distal peripheral LNs at 72 h after intranasal antigen administration. Data are representative of LNs from three separate mice.
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To see which cells expressed CD200 during the induction of tolerance we analyzed the nose-draining LNs, which have been shown to be essential for the induction of intranasal tolerance. In resting nosedraining LNs only stromal cells expressed CD200 (Figure 2c ), whereas upon OVA administration both stromal cells as well as activated T-cells expressed CD200 (Figures 2d and e) . In contrast, non-activated T-cells in distant LNs were mostly CD200 negative (Figure 2f ). Thus, both the micro-environment as well as activated T-cells can provide CD200R-expressing antigen-presenting DCs with the ligand CD200.
Increased resistance to tumors is associated with higher expression of pro-inflammatory cytokines by DCs in skin-draining LN The absence of CD200 expression on wild-type papilloma cells excludes the possibility that the intrinsic growth of papillomas is influenced by CD200, as well as a direct inhibition of immune cells by CD200-expressing tumor cells. The enhanced skin inflammation in Cd200 À/À mice prompted us to study the production of proinflammatory cytokines in the DCs from skin-draining LNs, the place where the adaptive immune response is initiated. We determined the expression of IL-1b and IL-6 in DCs and pDCs from mice undergoing the carcinogenesis protocol at 3 weeks of TPA treatment, when inflammation occurred, and after 20 weeks of treatment, at the end of the carcinogenesis protocol. We found that DCs from Cd200 À/À mice at the end of the carcinogenesis protocol produced more IL-1b mRNA than wild-type cells (Figure 3a) . Furthermore, pDCs from Cd200 À/À mice produced more IL-6 both after 3 weeks and 20 weeks of TPA treatment (Figure 3b ). Intracellular staining of ex vivo stimulated DCs showed increased IL-6 production both by pDCs and DCs of Cd200 À/À mice when compared with wild-type cells (Figure 3c ). Both DCs and pDCs expressed CD200R (Supplementary Figure S1 ). Expression was higher on inguinal LN DCs compared with pDCs from inguinal LN and pDCs and DCs from spleen. CD200R expression on spleen DCs and pDCs was not different between naive wildtype and Cd200 À/À mice (Supplementary Figure S1) .
mice upon TPA treatment Wild-type and Cd200 À/À mice undergoing the carcinogenesis protocol did not differ in the percentage of circulating CD4
þ T-cells and CD8 þ T-cells, and the percentage of naive, memory and effector T-cells (Supplementary Figure S2) . Because IL-1 and IL-6 promote the conversion of FoxP3 þ Treg cells to IL-17-producing FoxP3 þ cells, we concentrated on these subsets (Xu et al., 2007; Zhou et al., 2008; Chung et al., 2009) . We quantified Treg cells in a panel of LNs and spleen from naive and 3 week TPA-treated wildtype and Cd200 À/À mice, thus before the onset of first macroscopic papillomas (Figure 4a) . TPA application induced a threefold increase in Treg cells, which was comparable in wild-type and Cd200 À/À mice in all LN that were analyzed (Figure 4b ). In contrast, repetitive treatment with TPA resulted in a significantly higher number of CD4 þ IL-17 þ T-cells in the skin-draining axillary LN of Cd200 À/À mice compared with wild-type mice (Figure 4c ). We then analyzed the percentages of Figure 3 DCs from Cd200 À/À mice have increased IL-1b and IL-6 levels. (a, b) DCs from inguinal, axillary and brachial LNs from carcinogenesis subjected Cd200 À/À and wild-type mice were pooled, stained and sorted by flow cytometry. mRNA expression of IL-1b (a) and IL-6 (b) was analyzed by qreverse transcription(RT)-PCR in pooled cDNA samples from four different mice. As reference UBQ and HPRT were used. Median with range of two independent qRT-PCR reactions is depicted. (c) IL-6 expression in inguinal and axillary LN cells from mice treated for 20 weeks with TPA, and then stimulated ex vivo for 5 h with phorbol 12-myristate 13-acetate and ionomycin. Cells were gated for DCs (CD11c þ B220 À ) and pDCs (CD11c þ B220 þ ). Data are from two independent experiments and data were pooled (n ¼ 15). Significant differences are marked with *Po0.05 (unpaired t-test). (Figure 5a) . Strikingly, the observed increase in Th17 cells in Cd200 À/À mice was even more evident after 20 weeks of carcinogenesis (Figure 5b) . Again, the increase in Th17 cells in Cd200 À/À mice could specifically be attributed to an increased percentage of IL-17-producing FoxP3 þ cells, which showed a twofold increase in all skindraining LN, but not the spleen (Figure 5c ). Also the percentage of CD4 þ FoxP3
À IL-17 þ T-cells was increased in CD200-deficient mice but the differences were not as drastic as of CD4 þ FoxP3 þ IL-17 þ T-cells (Figure 5d ). Thus, the ability of Cd200 À/À mice to induce IL17-producing FoxP3 þ cells coincides with their resistance to skin tumor formation. To determine whether indeed (Figure 5f ). This suggests that CD4 þ FoxP3 þ RORg þ cells are preferentially targeted to the site of tumor growth.
Discussion
Here we show that the absence of CD200R-mediated inhibition precludes the development of immune 
-cells as percentage of CD4
þ T-cells from the inguinal, axillary, brachial and cervical LNs or spleens from Cd200 À/À and wild-type mice. Naive mice and mice subjected to short-term carcinogenesis (3 weeks) were used. For (b-e) single-cell suspensions from the organs were stimulated ex vivo for 5 h with phorbol 12-myristate 13-acetate and ionomycin in the presence of brefeldin A. Data are from two independent experiments and data were pooled (n ¼ 9), Bars indicate average and s.e.m. for each group. Significant differences are marked with *Po0.05, **Po0.01, or ***Po0.001 (unpaired t-test).
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TP Rygiel et al tolerance and increases anti-tumor immune responses. Importantly, we found a striking effect of the release of CD200-mediated inhibition on tumor outgrowth, irrespective of CD200 expression on the tumor. Antibodies that block CD200-CD200R interactions are currently being tested in clinical trials in patients with CD200-expressing tumors. Our findings suggest extension of the therapeutic use of CD200-CD200R blockers to patients with CD200-negative tumors. The source of CD200 to trigger CD200R still remains unclear, however there are several candidates. Our data show significant expression of LN stromal cells and in addition activated T-cells express significant levels of CD200. Alternatively, the CD200 signal may be supplied by tissue cells, for example, normal skin cells, which highly express CD200. Non-hematopoietic cells may deliver the initial CD200 signal, after which CD200 on T-cells could provide a feedback loop for the maintenance of tolerance. Expression of CD200 on hair follicle cells attenuates skin inflammation and enhances skin-graft survival (Gorczynski et al., 1999; Rosenblum et al., 2004 ). An inhibitory feedback loop between tolerogenic DC and Treg cells has been proposed previously and it is interesting to speculate on a role for CD200-CD200R herein (Min et al., 2003) . Intriguingly, a single study showed that CD200 deficiency can enhance tolerance, which correlates with increased Th2 cytokine production, but this has not been confirmed by others (Taylor et al., 2005) .
We show that tumor resistance of Cd200 À/À mice coincides with an inflammatory skin phenotype and the inability to develop immune tolerance to foreign antigens. It is likely that these processes are regulated by CD200-CD200R through the same mechanism. Notably, infection of Cd200 À/À mice with Neisseria meningitides or influenza virus causes increased production of pro-inflammatory cytokines, including IL-1b, IL-6, tumor necrosis factora and interferong (Snelgrove et al., 2008; Mukhopadhyay et al., 2010) . In our endogenous tumor model we also observed higher levels of the pro-inflammatory cytokines IL-1b and IL-6 in tumor-draining LN DCs derived from Cd200 À/À mice. We now show that this may also influence the adaptive immune response by shifting the T-cell balance toward Th17 cells.
Inhibition of the enzyme indoleamine-2,3-dioxygenase (IDO) has recently been shown to enhance Treg conversion to Th17 cells and increase anti-tumor immune response (Sharma et al., , 2010 . Moreover,
-cells as percentage of CD4
þ T-cells in the inguinal, axillary and cervical LNs or spleens isolated from Cd200 À/À and wild-type mice subjected to carcinogenesis for 20 weeks. For (b-d) single-cell suspensions from the organs were stimulated ex vivo for 5 h with phorbol 12-myristate 13-acetate and ionomycin in the presence of brefeldin A. The experiment was repeated twice and data were pooled (n ¼ 9). Bars indicate average and s.e.m. for each group. Significant differences are marked with *Po0.05, **Po0.01 or ***Po0.001 (unpaired t-test). 
A total of 14 different papillomas (both Cd200 À/À and wild-type), derived from two independent experiments, were stained and two fields for each sample were analyzed. LNs from five independent mice were analyzed as in Figure 4 . Median with range is depicted. CD200-CD200R signaling in tumorigenesis TP Rygiel et al it was published that induction of CD200R signaling in pDCs increases the expression of IDO (Fallarino et al., 2004) . Thus, CD200-deficient mice may have increased percentages of IL-17-producing FoxP3 þ cells due to impaired IDO activity. We tested this hypothesis and found no significant differences in IDO expression between DCs from Cd200 À/À and wild-type mice (Supplementary Figure S3A) . In addition, we did not see any differences in the kynurenine/tryptophan ratio in the sera of naive wild-type and Cd200 À/À mice (Supplementary Figure S3B) . Remarkably, we even observed a significantly higher kynurenine/tryptophan ratio in the sera of TPA-treated Cd200 À/À mice, suggesting a higher level of IDO activity in the latter. Lastly, systemic inhibition of IDO by subcutaneous implantation of slow-release pellets loaded with the IDO inhibitor 1-methl-D-tryptophan did not result in increased numbers of IL-17-producing FoxP3 þ cells when compared with placebo-treated mice, whereas Cd200 Figure S3C) . Therefore, we conclude that the increase in FoxP3 þ IL-17 þ T-cells in CD200-deficient mice is not caused by decreased IDO activity.
cells within the LNs (Supplementary
IL-17 has a dual role in tumor development and antitumor responses (Maniati et al., 2010) . IL-17 À/À mice have increased resistance for 7,12-dimethylbenzanthracene/TPA-induced skin tumors (Wang et al., 2010) whereas the same mice are less resistant to B16F10 melanoma (Kryczek et al., 2009) . It has been proposed that IL-17-mediated inflammation is tumor-promoting during the initial phase of tumor growth, whereas Th17 cells are anti-tumorigenic in established tumors (Wilke et al., 2011) . The biological relevance of FoxP3 þ IL-17 þ converted Treg cells or Th17 matured CD4 þ cells is supported by studies with tumor models, where these cells can induce anti-tumor CD8 þ T-cell responses (Martin-Orozco et al., 2009; Sharma et al., 2009 Sharma et al., , 2010 Figure S4A, S4B ). In addition, the number of CD8 þ T-cells in the papillomas did not significantly differ between wild-type and Cd200 À/À mice (Supplementary Figure S4C) . This is probably because of an analysis bias; because Cd200 À/À mice develop fewer tumors we automatically selected for the tumors that escaped immune attack and were not able to score tumors that were small or did not emerge, probably due to a potent immune response.
Our findings suggest that CD200-CD200R signaling is essential to regulate tolerance to external antigens and to tumors also in the absence of CD200 expression on the tumors. On the basis of our findings we propose a model where stimulation of CD200R on DCs by CD200 expressed on non-hematopoietic cells and/or T-cells regulates proinflammatory cytokine production. This in turn induces the generation of Treg cells and prevents conversion to FoxP3 þ IL-17 þ effector cells, resulting in a tolerant milieu. These data reveal two unanticipated aspects of CD200-CD200R blockade as therapy. First, the CD200-CD200R signaling pathway controls the Treg/Teffector cell balance and second, it provides a therapeutic opportunity for CD200 blocking antibodies irrespective of CD200 expression on tumor cells.
Materials and methods
Animals
Wild-type C57BL/6J 10-14 week-old female mice were obtained from Charles River (L'Arbresle, France). Female Cd200 À/À mice were made and maintained on a full C57BL/6J background (Hoek et al., 2000) and were bred at the specified pathogen-free unit at the Utrecht University Central Animal Laboratory. For the nasal tolerance experiments female C57BL/6J mice age 8-12 weeks were purchased from Charles River, whereas female Cd200 À/À mice were bred and obtained from the animal facility at the Amsterdam Medical Center, The Netherlands. The OT-II transgenic mice were used at 8-12 weeks of age and were bred at the VU Medical Center animal facility. All animal experiments were approved by the Utrecht University Ethical Committee for Animal Experimentation or the Animal Experiments Committee of the VU Medical Center or the Amsterdam Medical Center. All the experiments were conducted in accordance with current Dutch laws on animal experimentation.
Cell isolation and restimulation
Total cell recovery from spleen and LNs was comparable between Cd200 À/À and wild-type mice in all experiments. To obtain single-cell suspensions, spleens and LNs were forced through a 100 mm sieve. To remove erythrocytes, pelleted cells were resuspended in 150 mM NH 4 , 1 mM NaHCO 3 , pH 7.4 buffer, afterwards cells were centrifuged and washed resuspended in RPMI-1640 medium with 10% fetal calf serum. Cells were quantified using a CASY cell counter (Innovatis, Roche, Basel, Switzerland), stained with antibodies and analyzed by flow cytometry. Cells were cultured in RPMI-1640 medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Bodinco, Alkmaar, The Netherlands) and penicillin and streptomycin. For ex vivo stimulation 2 Â 10 6 cells were incubated for 5 h at 37 1C with phorbol 12-myristate 13-acetate (10 ng ml À1 ) and ionomycin (2 mg ml À1 ) and brefeldin A (BD Biosciences) was added during the last 4 h of culture.
Nasal tolerance model
Delayed-type hypersensitivity model responses were analyzed as described before (van der Marel et al., 2007) . To check for the presence of Treg cells in sensitized and tolerized mice, tolerized mice were resensitized by the same mix of OVA (Albumin Chicken Egg 5 Â Crystalline, Calbiochem, Merck, Darmstadt, Germany) and IFA (Difco Laboratories, Detroit, USA) 2 weeks after ear thickness measurement to maintain Treg cells. One week after resensitization spleen CD4 þ T-cells were enriched using the CD4-negative selection kit (Dynal, Oslo, Norway). The enriched cell suspension consisted of 50-60% CD4 þ T-cells, as determined by flow cytometry (FACS Calibur, Becton Dickinson and FACS Cyan, DakoCytomation, Glostrup, Denmark) . In all, 2-5 Â 10 5 CD4 þ T-cells were injected intravenously via the lateral tail vein in recipient mice, which were subsequently sensitized and challenged with OVA (as described above).
T-cell enrichment, carboxyfluorescein diacetate succinimidyl ester labeling, transfer and antigenic stimulation Spleens and LNs CD4 þ T-cells from OT-II mice were enriched as described above. The enriched cell suspension consisted of at least 60% CD4
þ T-cells, as determined by flow cytometry (FACS Calibur). These cells were labeled with 5 mM of carboxyfluorescein diacetate succinimidyl ester at 3 Â 10 7 /ml for 10 min and washed with ice-cold phosphate-buffered saline (PBS). C57BL/6 mice were injected with B10 7 OVA-specific T-cells and were subsequently stimulated by intranasal administration of 400 mg OVA in 10 ml saline. Draining cervical and distant peripheral LNs were analyzed at 72 h after antigen administration by either immunofluorescence or fluorescence-activated cell sorting.
Carcinogenesis protocol
For short (3 weeks) and long (20 weeks) two-stage chemical carcinogenesis mice were treated with 7,12-dimethylbenzanthracene and TPA as described earlier (Malliri et al., 2002) . All visible papillomas were enumerated biweekly and their diameter was measured with a caliper after they reached at least 1 mm. The condition of the skin was scored biweekly in the weeks following TPA application. Mice with dry skin on the back and with skin patches covered with dry flakes of epidermis were defined as having a dry skin.
Flow cytometry and cell sorting Cells were stained for 30 min at 4 1C in PBS containing 2% bovine serum albumin and 0.1%. NaN 3 . The anti-CD200 and anti-CD200R monoclonal antibodies were from Serotec (Du¨sseldorf, Germany). Monoclonal antibody to FoxP3 and CD11c were from BioLegend (San Diego, CA, USA), to IL-17 from eBioscience, San Diego, CA, USA. Anti-CD3, -CD4 and -CD8 were from BD Biosciences. FoxP3 and IL-17 intracellular staining was done with Fix/Perm buffer from eBioscience; other intracellular stainings were performed with Cytofix/Cytoperm and Perm/Wash buffers from BD Biosciences and used according to the manufacturer's instructions. Data were acquired on a FACSCalibur, and analyzed with CellQuest Pro software (BD Biosciences). For isolation of DCs, single-cell suspensions from pooled LNs were stained for CD11c and B220. Cells were sorted on a FACSAria (BD Biosciences) based on the expression of the following markers: DCs CD11c þ B220 À and pDCs CD11c þ B220 þ . LN stromal cells were sorted as all cells that were negative for the Alexa-488-conjugated anti-CD45 (clone MP33), whereas 7AAD þ dead cells were excluded.
Immunofluorescence
Tissues were embedded and frozen in OCT compound (Sakura Finetek Europe, The Netherlands), 7 mm cryosections were generated and fixed in acetone for 5 min. Sections were then pre-incubated in PBS supplemented with 5% (v/v) mouse serum for 15 min. Incubation with the primary or secondary antibodies was carried out for 30 min. For detection of RORg, sections were fixed in 1% formalin in PBS for 30 min, followed by incubation with PBS containing 0.1% Triton X-100 and 1% goat serum for
